Drick N, et al. - Researchers assessed the clinical efficacy of anti-interleukin-5 (IL-5) treatment in real-life setting and analysed potential predictors for treatment response, using simple criteria for treatment response applicable to all asthma patients. Using the simple criteria [increase of forced expiratory volume in one second (FEV₁) ≥ 12% or ≥ 200 ml, reduction of blood eosinophils (< 150/μl or < 80% from baseline) and improvement of subjective condition (patient-judged subjective improvement or worsening following therapy)], they analyzed data from 42 patients with severe eosinophilic asthma treated with mepolizumab for at least six months. Treatment responders were those who fulfilled two criteria. Findings demonstrated that anti-IL-5 therapy represents an effective treatment option in clinical practice as 76% of treated patients could be classified as treatment responders using a response criteria based on the improvement of lung function, decrease of eosinophils and improvement of subjective condition.